{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T03:25:37Z","timestamp":1770434737728,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2011,11,8]],"date-time":"2011-11-08T00:00:00Z","timestamp":1320710400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1007\/s00296-011-2216-0","type":"journal-article","created":{"date-parts":[[2011,11,7]],"date-time":"2011-11-07T08:20:12Z","timestamp":1320654012000},"page":"3481-3485","source":"Crossref","is-referenced-by-count":15,"title":["A case of leukoencephalopathy associated with adalimumab-treated rheumatoid arthritis and a review of literature"],"prefix":"10.1007","volume":"32","author":[{"given":"Yang-Seon","family":"Ryu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Hwan","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun-Ji","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Ki","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Hyeon","family":"Ju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho-Youn","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,11,8]]},"reference":[{"key":"2216_CR1","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1056\/NEJM199606273342607","volume":"334","author":"F Bazzoni","year":"1996","unstructured":"Bazzoni F, Beutler B (1996) The tumor necrosis factor ligand and receptor families. N Engl J Med 334:1717\u20131725","journal-title":"N Engl J Med"},{"key":"2216_CR2","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra032906","volume":"350","author":"NJ Olsen","year":"2004","unstructured":"Olsen NJ, Stein CM (2004) New drugs for rheumatoid arthritis. N Engl J Med 350:2167\u20132179","journal-title":"N Engl J Med"},{"key":"2216_CR3","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","volume":"53","author":"GW Barry","year":"1999","unstructured":"Barry GW et al (1999) TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53:457\u2013465","journal-title":"Neurology"},{"key":"2216_CR4","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/MD.0b013e318181e6af","volume":"87","author":"M Ramos-Casals","year":"2008","unstructured":"Ramos-Casals M, Solans R, Rosas J et al (2008) Primary Sj\u00f6gren syndrome in Spain: clinical and immunologic expression in 1,010 patients. Medicine (Baltimore) 87:210\u2013219","journal-title":"Medicine (Baltimore)"},{"key":"2216_CR5","first-page":"239","volume":"34","author":"L Bensouda-Grimaldi","year":"2007","unstructured":"Bensouda-Grimaldi L, Mulleman D, Valat JP et al (2007) Adalimumab-associated multiple sclerosis. J Rheumatol 34:239\u2013240","journal-title":"J Rheumatol"},{"key":"2216_CR6","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1002\/1529-0131(200109)44:9<1977::AID-ART345>3.0.CO;2-6","volume":"44","author":"WH Robinson","year":"2001","unstructured":"Robinson WH, Genovese MC, Moreland LW (2001) Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 44:1977\u20131983","journal-title":"Arthritis Rheum"},{"key":"2216_CR7","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1442-9071.2008.001741.x","volume":"36","author":"HH Do","year":"2008","unstructured":"Do HH, Mohamed A, Klistorner A et al (2008) Ophthalmic manifestations of demyelination secondary to etanercept. Clin Exp Ophthalmol 36:392\u2013394","journal-title":"Clin Exp Ophthalmol"},{"key":"2216_CR8","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10165-008-0062-z","volume":"18","author":"T Kameda","year":"2008","unstructured":"Kameda T, Dobashi H, Kittaka K et al (2008) A case of rheumatoid arthritis complicated by demyelination in both cerebral cortex and spinal cord during etanercept therapy. Mod Rheumatol 18:399\u2013402","journal-title":"Mod Rheumatol"},{"key":"2216_CR9","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","volume":"44","author":"N Mohan","year":"2001","unstructured":"Mohan N, Edwards ET, Cupps TR et al (2001) Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 44:2862\u20132869","journal-title":"Arthritis Rheum"},{"key":"2216_CR10","unstructured":"Food and Drug Administration, Center for Drug Evaluation and Research, Arthritis Advisory Committee. Safety update meeting on TNF blocking agents. March 4, 2003. Available from: http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/03\/transcripts\/3930T1.htm\/"},{"key":"2216_CR11","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.semarthrit.2010.06.004","volume":"40","author":"MC Fern\u00e1ndez-Espartero","year":"2011","unstructured":"Fern\u00e1ndez-Espartero MC et al (2011) Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. Semin Arthritis Rheum 40:330\u2013337","journal-title":"Semin Arthritis Rheum"},{"key":"2216_CR12","doi-asserted-by":"crossref","unstructured":"Ainhi D et al (2011) Parkinsonism and dystonia associated with adalimumab [letter]. Mov disord 26(8):1556\u20131558","DOI":"10.1002\/mds.23548"},{"key":"2216_CR13","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1212\/WNL.57.10.1885","volume":"57","author":"NL Sicotte","year":"2001","unstructured":"Sicotte NL, Voskuhl RR (2001) Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 57:1885\u20131888","journal-title":"Neurology"},{"key":"2216_CR14","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/s00415-005-0055-1","volume":"253","author":"M Bellesi","year":"2006","unstructured":"Bellesi M, Logullo F et al (2006) CNS demyelination during anti-tumor necrosis factor alpha therapy. J Neurol 253:668\u2013669","journal-title":"J Neurol"},{"key":"2216_CR15","first-page":"239","volume":"34","author":"L bensouda-grimaldi","year":"2007","unstructured":"bensouda-grimaldi L et al (2007) Adalimumab-associated multiple sclerosis. J Rheumatol 34:239","journal-title":"J Rheumatol"},{"key":"2216_CR16","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1056\/NEJM199108153250704","volume":"325","author":"MK Sharief","year":"1991","unstructured":"Sharief MK, Hentges R (1991) Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 325:467\u2013472","journal-title":"N Engl J Med"},{"key":"2216_CR17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1600-065X.1999.tb01315.x","volume":"169","author":"G Kollias","year":"1999","unstructured":"Kollias G, Douni E, Kassiotis G, Kontoyiannis D (1999) On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol Rev 169:175\u2013194","journal-title":"Immunol Rev"},{"issue":"9","key":"2216_CR18","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1002\/1529-0131(200109)44:9<1977::AID-ART345>3.0.CO;2-6","volume":"44","author":"WH Robinson","year":"2001","unstructured":"Robinson WH, Genovese MC, Moreland LW (2001) Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 44(9):1977\u20131983","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2216_CR19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.nbd.2004.07.015","volume":"17","author":"S Sotgiu","year":"2004","unstructured":"Sotgiu S, Pugliatti M, Fois ML, Arru G, Sanna A, Sotgiu MA et al (2004) Genes, environment, and susceptibility to multiple sclerosis. Neurobiol Dis 17(2):131\u2013143","journal-title":"Neurobiol Dis"},{"issue":"5","key":"2216_CR20","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1001\/archneurol.2009.49","volume":"66","author":"A Rovira","year":"2009","unstructured":"Rovira A, Swanton J, Tintore M, Huerga E, Barkhof F, Filippi M et al (2009) A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis. Arch Neurol 66(5):587\u2013592","journal-title":"Arch Neurol"},{"issue":"6","key":"2216_CR21","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/1531-8249(199906)45:6<695::AID-ANA3>3.0.CO;2-R","volume":"45","author":"AH Boxel-Dezaire Van","year":"1999","unstructured":"Van Boxel-Dezaire AH, Hoff SC, Van Oosten BW, Verweij CL, Drager AM, Ader HJ et al (1999) Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann Neurol 45(6):695\u2013703","journal-title":"Ann Neurol"},{"key":"2216_CR22","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1212\/WNL.38.3.371","volume":"38","author":"J Keyser De","year":"1988","unstructured":"De Keyser J (1988) Autoimmunity in multiple sclerosis. Neurology 38:371\u2013374","journal-title":"Neurology"},{"key":"2216_CR23","first-page":"1027","volume":"33","author":"E Toussirot","year":"2006","unstructured":"Toussirot E, Pertuiset E, Martin A et al (2006) Association of rheumatoid arthritis with multiple sclerosis: report of 14 cases and discussion of its significance [letter]. J Rheumatol 33:1027\u20131028","journal-title":"J Rheumatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-011-2216-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-011-2216-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-011-2216-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T01:13:24Z","timestamp":1560906804000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-011-2216-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,8]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["2216"],"URL":"https:\/\/doi.org\/10.1007\/s00296-011-2216-0","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,8]]}}}